Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/11/037702
CTRI/2021/11/037702
Recruiting
Phase 3

Minimal residual disease guided therapy in newly diagnosed multiple myeloma. - Safetyof MRD guided VRd consolidation

Intramural grant of Tata Memorial Center Mumbai0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: C900- Multiple myeloma

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: C900- Multiple myeloma
Sponsor
Intramural grant of Tata Memorial Center Mumbai
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Intramural grant of Tata Memorial Center Mumbai

Eligibility Criteria

Inclusion Criteria

  • •1\.patient with histologically proven PCNSL
  • •2\. Received methotrexate based induction therapy
  • •3\. Radio logical consolidation therapy after achieving CR
  • •5\.Age \>18 years
  • •6\.PS \>2 after the completion of consolidation therpy
  • •7\.Adequate bone marrow function with absolute leukocytes \>2000mm3,neutrophil count ANC \>1000/mm3\.haemoglobin \>8g/dl and platelets \>100000/mm3
  • •8\.Adecute liver function with serum SGOT/AST or SGPT/ALT \<3\.0Xupper limit of Normal ULN;bilirubin \<1\.5XLNS
  • •9\.Creatinineclearance \>30ml/min.Patients with calculated ceratine cleearance between 30 and 60 ml/min lenalidomide dose will be adjusted as follows(10 mg oncedalily)
  • •10\.Able to take aspirin(75mg) daily as prophylactic anticoagulant
  • •11\.Able to understand the teratogenicity

Exclusion Criteria

  • •Diagnosis of sleep apnea or any other chronic respiratory disease
  • •Any acute or chronic condition that would limit the ability of the patient to participate in the study
  • •Refusal to give informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNon-Small Cell Lung Cancer
NCT06709274Guangdong Association of Clinical Trials342
Completed
Not Applicable
Prospective evaluation of minimal residual disease in acute myeloid leukemia using TIM-3 as a leukemia markeracute myeloid leukemia
JPRN-UMIN000030977Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine50
Active, not recruiting
Not Applicable
Eradication of Minimal Residual Disease (MRD) in patients with Chronic Lymphocytic Leukaemia (CLL) with Alemtuzumab: A Phase II Study - UKCLL07Chronica Lymphocytic Leukaemia (CLL)
EUCTR2006-000053-22-GBeeds Teaching Hospitals NHS Trust54
Completed
Not Applicable
Treatment guided by detection of Minimal Residual Disease after allogeneic stem cell transplantation in Acute Myeloid Leukaemiaacute myeloid leukemiaAML10024324
NL-OMON38951Vrije Universiteit Medisch Centrum31
Active, not recruiting
Not Applicable
Treatment guided by detection of Minimal Residual Disease after allogeneic stem cell transplantation in Acute Myeloid LeukaemiaMinimal residual disease after allogeneic stem cell transplantation in Acute Myeloid LeukaemiaMedDRA version: 15.1Level: LLTClassification code 10001941Term: AMLSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2013-000238-37-NLVU University medical center